Accuray Incorporated (NASDAQ:ARAY) stock has received a short term price target of $ 10.5 from 4 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $1.73. The higher estimate of target price is $12 , while the lower price target estimate is $8
Company shares have received an average consensus rating of Hold for the current week
On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CEO of Accuray Inc, Levine Joshua, had purchased 50,000 shares in a transaction dated on November 9, 2015. The transaction was executed at $7.12 per share with total amount equaling $356,000.
Accuray Incorporated (NASDAQ:ARAY) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.15 points or 2.83% at $5.15 with 1,133,487 shares getting traded. Post opening the session at $5.28, the shares hit an intraday low of $5.13 and an intraday high of $5.378 and the price was in this range throughout the day. The company has a market cap of $417 million and the number of outstanding shares have been calculated to be 80,924,480 shares. The 52-week high of Accuray Incorporated (NASDAQ:ARAY) is $7.54 and the 52-week low is $4.8.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures, sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy and adaptive radiation therapy. Its principal radiosurgery products, the CyberKnife Systems are robotic full-body radiosurgery system designed to treat tumors anywhere in the body non-invasively, which include the CyberKnife M6 Series with configuration options of fixed collimators plus iris variable aperture collimator, fixed collimators plus the InCise MLC and fixed collimators plus iris variable aperture collimator and the InCise MLC. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.